Epilepsy Therapeutics in Asia-Pacific Markets to 2024 - Uptake of Novel Therapies and Rising Awareness is Expected to Drive the Market Growth

  • ID: 4701594
  • Report
  • Region: Asia Pacific
  • 120 Pages
  • GBI Research
1 of 5

FEATURED COMPANIES

  • BIAL-Portela
  • Eisai
  • GSK
  • GW Pharmaceuticals
  • Pfizer
  • SK Biopharmaceuticals
  • MORE

Epilepsy is a chronic medical disorder or condition in which the brain is overactive, sending too many signals, usually resulting in unpredictable, unprovoked recurrent seizures that affect a variety of mental and physical functions. Epilepsy is the fourth most common neurological disorder, affecting more than 65 million individuals worldwide. Epilepsy can start at any age, but is most commonly diagnosed in people under 20 and people over 65. This is because some causes are more common in young people (such as difficulties at birth, childhood infections or accidents) and in older people (such as strokes that lead to epilepsy).

Epilepsy treatment has historically been dominated by gamma aminobutyric acid (GABA) modulators and sodium channel blockers, leaving a wide unmet need intact in a sizeable section of patients who do not respond to the existing treatment options. Historically there is a lack of potent disease modifying or curative drugs in the epilepsy therapeutic space. The dominant older generation AEDs had poor safety and tolerability profiles. Second generation AEDs with newer mechanisms of action; signaled a shift in this trend in the last decade with improved tolerability and efficacy.

Epilepsy market in the five major geographies in the Asia-Pacific (APAC) region (Australia, China, India, Japan and South Korea) is expected to increase at a compound annual growth rate (CAGR) of 3.5% to reach $1.75 billion in 2024. The value of the market is expected to grow more rapidly in India and China compared with the more developed markets, Japan and Australia. With a high prevalence, these two regions have large treatment populations, which are expected to grow further due to better healthcare access and improvements in treatment gaps.

The late-stage pipeline contains promising therapies that have the potential to achieve approval and launch during the forecast period. These drugs are under development with novel mechanisms of actions that are not conventional in the epilepsy market and are expected to provide greater efficacy and safety than previous AEDs. The launch and uptake of these new pipeline therapies with better efficacy are expected to drive APAC market growth.

Scope

  • The APAC epilepsy market will be valued at $1.7 billion in 2024, growing from $1.4 billion in 2017 at a CAGR of 3.5%.
  • How will the approval of Cenobamate for treatment-resistant epilepsy affect the competitive landscape, with no therapy currently available to address this patient subset?
  • The epilepsy market is crowded with cheap, generic, “me-too” drugs. What are the main barriers a new therapy faces when entering the epilepsy market?
  • The pipeline for epilepsy therapy is not diverse in terms of molecule type and molecular targets.
  • How have the late-stage therapies performed in clinical trials?
  • The level of unmet need in the epilepsy market is high. Will the pipeline drugs fulfill these unmet needs?
  • The market forecasts indicate that India and China will contribute the most to the APAC market.
  • How will the annual cost of therapy and market size vary between the five assessed APAC markets?
  • How will the growing population affect the market?
  • How will the various drivers and barriers influence the market over the forecast period?
  • Licensing deals are the most common form of strategic alliance in epilepsy, with total deal values ranging from under $0.1m to over $820m.
  • How do deal frequency and value compare between target families and molecule types?

Reasons to buy

  • This report will enable you to:
  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the epilepsy market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
  • Analyze the epilepsy pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict epilepsy market growth in the five assessed APAC markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the epilepsy deals landscape by analyzing trends in licensing and co-development deals.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • BIAL-Portela
  • Eisai
  • GSK
  • GW Pharmaceuticals
  • Pfizer
  • SK Biopharmaceuticals
  • MORE

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Introduction
2.2 Epidemiology
2.3 Disease Classification
2.4 Symptoms
2.5 Etiology and Pathophysiology
2.5.1 Etiology
2.5.2 Pathophysiology
2.6 Diagnosis
2.6.1 Biomarkers
2.7 Prognosis
2.8 Treatment Guidelines and Options
2.8.1 Treatment Options

3 Marketed Products
3.1 Overview
3.1.1 Aptiom/Zebinix (Eslicarbazepine acetate) - BIAL-Portela
3.1.2 Banzel/Inovelon (Rufinamide) - Novartis
3.1.3 Briviact (Brivaracetam) - UCB
3.1.4 Fycompa (perampanel) - Eisai
3.1.5 Keppra (levetiracetam) - UCB
3.1.6 Lyrica (pregabalin) - Pfizer
3.1.7 Vimpat (lacosamide) - UCB
3.1.8 Lamictal (lamotrigine) - GSK
3.1.9 Epidiolex (Cannabidiol) - GW Pharmaceuticals
3.1.10 Older Generation AEDs
3.2 Comparative Efficacy and Safety of Marketed Product

4 Pipeline Analysis
4.1 Overview
4.2 Pipeline Distribution by Stage of Development, Molecule Type, Route of Administration and Program Type
4.3 Pipeline Distribution by Molecular Target
4.4 Promising Pipeline Candidates
4.4.1 Fintepla (low-dose fenfluramine Hydrochloride/ZX-008) - Zogenix
4.4.2 Cenobamate (YKP3089) - SK Biopharmaceuticals
4.5 Comparative Efficacy and Safety of Pipeline Products
4.6 Product Competitiveness Framework

5 Clinical Trial Analysis
5.1 Failure Rate
5.1.1 Overall Failure Rate
5.1.2 Failure Rate by Phase and Molecule Type
5.1.3 Failure Rate by Phase and Molecular Target
5.2 Clinical Trial Size
5.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development
5.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development
5.2.3 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development
5.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development
5.3 Clinical Trial Duration
5.3.1 Clinical Trial Duration by Molecule Type
5.3.2 Clinical Trial Duration by Molecular Target
5.4 Competitive Clinical Trials Metrics Analysis

6 Multi-scenario Forecast
6.1 Geographical Markets
6.2 Asia-Pacific Market
6.3 India
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Therapy
6.3.3 Market Size
6.4 China
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Therapy
6.4.3 Market Size
6.5 Australia
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Therapy
6.5.3 Market Size
6.6 South Korea
6.6.1 Treatment Usage Patterns
6.6.2 Annual Cost of Therapy
6.6.3 Market Size
6.7 Japan
6.7.1 Treatment Usage Patterns
6.7.2 Annual Cost of Therapy
6.7.3 Market Size

7 Drivers and Barriers
7.1 Drivers
7.1.1 Improved Economy and Affordability Boost the Market
7.1.2 Promising Pipeline Products that Target Unmet Needs for Epilepsy
7.1.3 Government-Sponsored Increased Awareness and Access to Healthcare will Improve Epilepsy Treatment
7.2 Barriers
7.2.1 Social Stigma and Lack Awareness to Hamper Low Diagnosis and Treatment Rates
7.2.2 Impending Patent Cliffs and Generic Erosion
7.2.3 Lack of Strong Patent Protection or Intellectual Property Rights.

8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.1.1 Deals by Region and Value
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.2 Key Licensing Deals
8.3 Co-development Deals
8.3.1 Deals by Region and Value
8.3.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.3.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.4 Key Co-development Deals

9 Appendix
9.1 All Pipeline Drugs by Stage of Development
9.1.1 Discovery
9.1.2 Preclinical
9.1.3 IND/CTA-filed
9.1.4 Phase I
9.1.5 Phase II
9.1.6 Phase III
9.1.7 Pre-registration
9.2 Summary of Multi-scenario Market Forecasts to 2024
9.2.1 Asia-Pacific
9.2.2 India
9.2.3 China
9.2.4 Australia
9.2.5 South Korea
9.2.6 Japan
9.3 Bibliography
9.4 Abbreviations
9.5 Research Methodology
9.5.1 Secondary Research
9.5.2 Marketed Product Profiles
9.5.3 Late-Stage Pipeline Candidates
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
9.5.5 Product Competitiveness Framework
9.5.6 Pipeline Analysis
9.5.7 Forecasting Model
9.5.8 Deals Data Analysis
9.6 Contact Us
9.7 Disclaimer

List of Tables
Table 1: Epilepsy Therapeutics, Global, Types of Seizures, 2017
Table 2: Causes of Epilepsy According to Age
Table 3: Examples of Biomarkers Needed in Different Epilepsy Indications
Table 4: AED Options by Seizure Type
Table 5: Epilepsy Therapeutics Market, Global, Licensing Deals Valued Above $10m, 2007-2018
Table 6: Epilepsy Therapeutics Market, Global, Co-development Deals, 2007-2018
Table 7: Epilepsy Therapeutics Market, Global, All Pipeline Products, Discovery, 2018
Table 8: Epilepsy Therapeutics Market, Global, All Pipeline Products, Preclinical, 2018
Table 9: Epilepsy Therapeutics Market, Global, All Pipeline Products, IND/CTA-filed, 2018
Table 10: Epilepsy Therapeutics Market, Global, All Pipeline Products, Phase I, 2018
Table 11: Epilepsy Therapeutics Market, Global, All Pipeline Products, Phase II, 2018
Table 12: Epilepsy Therapeutics Market, Global, All Pipeline Products, Phase III, 2018
Table 13: Epilepsy Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2018
Table 14: Epilepsy Therapeutics Market, Asia-Pacific, Market Forecast, 2017-2024
Table 15: Epilepsy Therapeutics Market, India, Market Forecast, 2017-2024
Table 16: Epilepsy Therapeutics Market, China, Market Forecast, 2017-2024
Table 17: Epilepsy Therapeutics Market, Australia, Market Forecast, 2017-2024
Table 18: Epilepsy Therapeutics Market, South Korea, Market Forecast, 2017-2024
Table 19: Epilepsy Therapeutics Market, Japan, Market Forecast, 2017-2024

List of Figures
Figure 1: Epilepsy Therapeutics Market, Patient Distribution in APAC
Figure 2: Summary of the Pathophysiology of Seizures by Net Increased Neuronal Excitation
Figure 3: Algorithm for investigation of patient presenting with seizure
Figure 4: Algorithm for Choice of AED for New-Onset Epilepsy Patients
Figure 5: Treatment Algorithm for Status Epilepticus in Australia
Figure 6: Epilepsy Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products
Figure 7: Pipeline for Epilepsy Therapeutics, Global, 2018
Figure 8: Pipeline for Epilepsy Therapeutics by Molecular Target, Global, 2018
Figure 9: Epilepsy Therapeutics Market, APAC, ZX008 Forecast ($m), 2020-2024
Figure 10: Epilepsy Therapeutics Market, APAC, Cenobamate Forecast ($m), 2020-2024
Figure 11: Epilepsy Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products
Figure 12: Epilepsy Therapeutics Market, Competitor Matrix for Epilepsy Marketed and Pipeline Products
Figure 13: Epilepsy Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2007-2017
Figure 14: Epilepsy Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2007-2017
Figure 15: Epilepsy Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2007-2017
Figure 16: Epilepsy Therapeutics, Global, Clinical Trial Size per Product by Molecular Target (participants), 2007-2017
Figure 17: Epilepsy Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2007-2017
Figure 18: Epilepsy Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2007-2017
Figure 19: Epilepsy Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2007-2017
Figure 20: Epilepsy Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2007-2017
Figure 21: Epilepsy Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
Figure 22: Epilepsy Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
Figure 23: Epilepsy Therapeutics Market, Asia-Pacific, Treatment Patterns (million), 2017-2024
Figure 24: Epilepsy Therapeutics Market, APAC, Market Size ($m), 2017-2024
Figure 25: Epilepsy Therapeutics Market, India, Treatment Patterns (million), 2017-2024
Figure 26: Epilepsy Therapeutics Market, India, Annual Cost of Therapy ($), 2017-2024
Figure 27: Epilepsy Therapeutics Market, India, Market Size ($m), 2017-2024
Figure 28: Epilepsy Therapeutics Market, China, Treatment Patterns (million), 2017-2024
Figure 29: Epilepsy Therapeutics Market, China, Annual Cost of Therapy ($), 2017-2024
Figure 30: Epilepsy Therapeutics Market, China, Market Size ($m), 2017-2024
Figure 31: Epilepsy Therapeutics Market, Australia, Treatment Patterns (‘000), 2017-2024
Figure 32: Epilepsy Therapeutics Market, Australia, Annual Cost of Therapy ($), 2017-2024
Figure 33: Epilepsy Therapeutics Market, Australia, Market Size ($m), 2017-2024
Figure 34: Epilepsy Therapeutics Market, South Korea, Treatment Patterns (‘000), 2017-2024
Figure 35: Epilepsy Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2017-2024
Figure 36: Epilepsy Therapeutics Market, South Korea, Market Size ($m), 2017-2024
Figure 37: Epilepsy Therapeutics Market, Japan, Treatment Patterns (000), 2017-2024
Figure 38: Epilepsy Therapeutics Market, Japan, Annual Cost of Therapy ($), 2017-2024
Figure 39: Epilepsy Therapeutics Market, Japan, Market Size ($m), 2017-2024
Figure 40: Epilepsy Therapeutics Market, Global, Licensing Deals By Region And Value, 2007-2018
Figure 41: Epilepsy Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007-2018
Figure 42: Epilepsy Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007-2018
Figure 43: Epilepsy Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2007-2018
Figure 44: Epilepsy Therapeutics Market, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2007-2018
Figure 45: Epilepsy Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2007-2018
Figure 46: Epilepsy Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2008-2018
Figure 47: Epilepsy Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007-2018
Figure 48: Epilepsy Therapeutics Market, Global, Co-development Deals by Molecule Type and Stage of Development, 2007-2018
Figure 49: Epilepsy Therapeutics Market, Global, Co-development Deals by Molecular Target, 2007-2018

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • BIAL-Portela
  • Eisai
  • GSK
  • GW Pharmaceuticals
  • Pfizer
  • SK Biopharmaceuticals
  • UCB
  • Zogenix
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll